Novartis to spinoff Alcon

In the event that all approvals are secured, the planned spinoff is expected to be completed in the first half of 2019. 

Novartis to spinoff Alcon
Colin Kerr
Colin Kerr
Published: Tuesday, July 3, 2018
 

Novartis has announced its intention to spinoff Alcon  into a separately-traded standalone company.

Joerg Reinhardt, Chairman of Novartis, said: “Our strategic review examined all options for Alcon ranging from retention, sale, IPO to spinoff. The review concluded that a spinoff would be in the best interests of Novartis shareholders and the Board of Directors intends to seek shareholder approval for a spinoff at the 2019 AGM. This transaction would allow our shareholders to benefit from potential future successes of a more focused Novartis and a standalone Alcon, which would become a publicly traded global medtech leader based here in Switzerland.”

The successful completion of the planned spinoff is subject to general market conditions, regulatory approvals, final Board of Directors endorsement and shareholder approval.  In the event that all approvals are secured, the planned spinoff is expected to be completed in the first half of 2019.

In addition to being incorporated in Switzerland, the intention would be to list shares of Alcon on the SIX Swiss Exchange and the New York Stock Exchange, said a Novartis spokesman.

Tags: novartis
Latest Articles
Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...

Update on Astigmatism Analysis

Read more...

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

Read more...

iNovation Innovators Den Boosts Eye Care Pioneers

New ideas and industry, colleague, and funding contacts among the benefits.

Read more...

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Read more...

José Güell: Trends in Cornea Treatment

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Read more...

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Read more...

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Read more...

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Read more...

Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...